Biogen Anti-LINGO MS Study Failure Removes Upside
This article was originally published in The Pink Sheet Daily
Biogen’s potential game-changing multiple sclerosis drug anti-LINGO-1 failed to meet the primary or secondary endpoints of a Phase II study, highlighting the challenges the biotech faces developing treatments for serious CNS disorders.
You may also be interested in...
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
Orna is retaining full ownership of its "crown jewel," in situ CAR programs for cancer. CEO Tom Barnes talked to Scrip about the deal and Orna's business strategy.
The pediatric market represents 70%-75% of the market for pneumococcal vaccines; Merck & Co.'s Vaxneuvance was already approved for infants earlier this year.